Pierre R. Brondeau
Analyst · Bank of America
Thank you, Alisha, and good morning, everyone. In the release, you saw that we generated $942 million in revenues, an increase of 3% over the first quarter of last year. We delivered $0.95 in adjusted EPS, a decrease of 12% over last year, largely due to lower earnings in Agricultural Solutions. This was driven by the widely reported weather factors that impacted the entire industry. Combined with currency movements, the lower ag performance reduced EPS by approximately $0.30 compared to the guidance we gave just over 3 months ago. Offsetting this, were strong results in Health and Nutrition and Minerals, with both segments returning results in line with our guidance and well ahead of the same period last year. First quarter sales in Agricultural Solutions were $467 million, down 6%, and segment earnings were $120 million, down 26%. Segment operating margin was lower compared to the prior year primarily due to unfavorable foreign exchange impacts, continued investments in sales, marketing and technical personnel and changes in product mix caused by difficult weather conditions. As we mentioned on our last earnings call, we were encouraged by the prospects in North America and Brazil, and we had expected segment earnings to be up low-teens percent. We had seen strong early demand in North America for 2 emerging products: Capture LFR insecticides and Authority herbicides. The increasing concern over corn rootworm and glyphosate-resistance supported our expectation that these brands would continue to outpace market growth throughout the first and second quarters of 2014. However, as the actually cold weather persisted throughout the quarter and into April, farmers delayed their use of these products, and it became clear that product wasn't moving through the distributions channels. In Brazil, our results were impacted by the record-breaking drought in São Paulo state. This is the region that represents 61% of the country's sugarcane market, the market in which FMC holds over 20% share with a broad portfolio of insecticide and herbicide. Our herbicide products are important in sugarcane, as they control difficult weeds that can severely impact yields. The drought conditions reduced crop replanting that would have normally taken place during this growing season, resulting in fewer herbicide applications compared to the previous year. Compared to our initial guidance, the adverse weather conditions in North America and Brazil reduced adjusted earnings in the first quarter by approximately $0.25 per share, with unfavorable currency movement, reducing earnings by a further $0.04 per share. Looking across quarters, we had a very successful 2013-14 season in Latin America. We are extremely pleased with the advances that were made in expanding our Latin American soybean presence and our market position in these crops, such as tomatoes and potatoes, segments that leverage our portfolio of insecticide and fungicide. In Brazil, we successfully launched Locker, a new 3-way fungicide for soybeans, and we gained traction with Talisman, a broad-spectrum insecticide for use in both soybeans and cotton. We also grew in Southern Brazil by expanding our relationship with cooperatives and further strengthening our most important customer relationship with another successful year of customer events. As widely reported, planting in North America remains later than historical averages. We now believe that the combination of delayed planting and lower corn acres could result in fewer applications of Capture LFR to control corn rootworm. However, we remain confident that the change in crop mix toward additional soybean acres will be favorable to us and will drive increased demand for Authority brand in herbicide. These products provide superior control of glyphosate-resistant weeds from growers throughout the Midwest and South. We also continue to focus on our strong presence in these crops, such as sunflowers and rice, that contribute to growth opportunity in this region. In 2014, we are strengthening our portfolio with several new product introductions into key segments within both North and Latin America. We have developed 3 new herbicide products for corn, Anthem, Solstice and Marvel, which will complement our resistance management portfolio in North America. Additionally, in the second half of the year, we expect strong market reception in Brazil, as we introduce our new cotton fungicide, Eclipse, and expand our Rugby insecticide into soybeans. Our strong customer relationships, along with these new product introductions, would allow us to further benefit from the expected increases in soybean and cotton acres. With the second quarter earnings increasing high teens to low 20% and the second half up approximately 35% versus the previous year, we expect that 2014 will follow a different pattern from our original outlook. However, a second half year-on-year increase above 30% is not unprecedented and is actually in line with what we have seen in recent years. We will compensate for the potential loss of some Capture LFR sales in North America in multiple ways. There will be a recovery in Q2 and early Q3 of delayed first quarter sales. We are seeing a favorable change in crop mix toward additional soybean acres in Brazil and North America, combined with a strong cotton and soybean planting season in Latin America in the second half of the year. We continue to gain market share in corn, soybean and cotton, driven by the strong portfolio of new products. Given these factors, we are highly confident in achieving outlook of mid-teens percent year-on-year growth in 2014, leading to another record year of earnings. In conclusion, our existing portfolio continues to demonstrate its resilience. We continue to gain market share in soybean and corn, and we are successfully introducing new products, including the 7 major brands already mentioned today. In addition, we have a very rich pipeline of products in development, including our Biosolutions research. Our innovation engine will continue to make FMC the fastest-growing ag company for years to come. Now turning to Health and Nutrition. Segment revenues of $226 million increased 18%, and operating profit of $51 million was up 17% over last year. In the quarter, demand for colloidal MCC and carrageenan-based ingredients increased in Nutrition end markets. We continue to work closely with our customers to help develop new applications for protein delivery such as our non-milk in North America and cereal-based beverages in Asia. Our new Thailand MCC plant, which is expected to start at the beginning of 2015, will support our growth in Asia. In Health end markets, we saw robust demand for our pharmaceutical excipients, especially binders, which was consistent with our expected growth rate and confirmed our view that overall pharmaceutical demand has returned to historical growth patterns. Our Avicel platform continues to benefit from a strong brand recognition. As we expand our product portfolio to include new encapsulation solutions and Omega-3 offerings, we expect to leverage our resources and deliver higher growth rates from our Health portfolio than we have seen historically. In Omega-3, our new Seal Sands facility received the necessary regulatory approvals, and we delivered our first customer shipments of pharmaceutical-grade products. Seal Sands utilizes advanced technology to manufacture high-purity, high-concentration products that command a premium price over low-concentration Omega-3 and is essential for pharmaceutical-grade applications. We were pleased to see 3 new prescription formulations of Omega-3s approved by the FDA earlier this year. We see this as a positive development for near-term demand for our products. Our technology allows us to efficiently serve the pharmaceutical market and, over time, will enable cost-effective penetration into the high-concentration Nutraceutical end markets. The Health and Nutrition business faced some headwinds during the first quarter. Asian currency movements and continued increases in seaweed cost had a modest impact on business performance. We have been working closely with customers in successfully offsetting this higher cost through a combination of price increases, ingredient substitutions and reformulation that create new solutions to meet their market needs. Looking forward, in Health and Nutrition, we expect second quarter segment earnings to increase low-teens percent over the previous year. In light of the strong first quarter performance and trends in the Health and Nutrition end market, we continue to expect that full year segment earnings will increase mid-teens percent. Now let me review Minerals. In the quarter, revenues of $249 million increased 11%, and operating profit of $37 million increased 27%. The businesses performed as planned, with improved operations, resulting in additional production volume. In Alkali Chemicals, revenue of $185 million were 2% higher than last year. As anticipated pricing, excluding freight charges, was above the previous year, the most notable increase in Asian export prices. Higher products and volume in the quarter also contributed to the sales growth. Revenues increases were partially offset by higher energy cost. Prolonged cold weather contributed to a spike in natural gas prices that was unfavorable in the quarter. Additionally, our contract prices for coal were higher than last year. We are looking at alternatives to reduce this cost, including renegotiation of our coal contract and alternative supply sources. In Lithium, revenues of $64 million increased 45% over the previous year. Higher volumes out of Argentina allowed us to take advantage of increased demand for Lithium, particularly in energy storage application. Pricing remained stable during the quarter, with product mix more heavily weighted toward primaries, which account for most of the volume growth. The business achieved a low-teens operating margin in the quarter despite continued inflation headwinds in Argentina. We expect the operating margin to continue improving sequentially throughout 2014. Looking at the second quarter, segment earnings in Minerals are expected to be up low-teens percent over the second quarter of 2013, driven mainly by increases in volume. For the full year, we expect segment earnings to increase high-teens percent in 2014. As we described during our last earnings call, our outlook for Alkali Chemicals only includes price increases that are specified in existing short- and long-term contracts. We remain optimistic that the soda ash pricing environment is improving, and we continue to be very supportive of ANSAC's efforts to pursue additional price gains in export markets. We remain confident that we'll produce record volumes as we operate within normal geological conditions and continue to benefit from higher products and volumes as a result of the Manufacturing Excellence programs. In Lithium, higher production volumes supporting increased demand will be the largest driver of improved business performance. Increased sales in primaries are expected to significantly contribute to revenue and earnings growth in 2014. However, it is important to remember that more than half of our production is further processed into downstream products. We maintain leading-market position in these downstream segments, and we'll continue to manage our supply to maximize overall margin. We remain confident in our ability to continue delivering operating margin improvement sequentially throughout this year. Turning to our outlook. For the second quarter, we expect to deliver adjusted earnings of $1.05 to $1.15 per diluted share, a 17% increase versus the second quarter of 2013, at the midpoint of the range. Although weather resulted in a slower-than-anticipated start in ag, we expect a strong second quarter performance, with segment earnings of high teens to 20% over the second quarter 2013. In Health and Nutrition, we expect to deliver a low-teens percentage increase in segment earnings, driven by strong demand across all product categories and in all major end markets. In Minerals, our outlook includes continued Lithium margin improvement and sequential pricing improvement in soda ash. This combination, along with higher production volume in both businesses, is expected to increase segment earnings by low-teens percent compared to the second quarter 2013. For the full year, our expectation of adjusted earnings continues to be $4.35 to $4.55 per diluted share, a 15% increase over 2013, at the midpoint of the range. We are maintaining our outlook for full year revenues in segment earnings in Agricultural Solutions to be at mid-teens percent over the previous year. The second half of the year is expected to show strong results, driven by increased soybean and cotton acreage in Latin America, improved sugarcane production in Brazil, new product introduction and our investment in market access channel around the world will continue to strengthen our customer relationship. We are confident 2014 would be another record year for ag, building on the 10 previous years of record performance. In Health and Nutrition, we anticipate full year revenue growth of mid- to high-teens percent, with segment earnings up mid-teens percent over 2013. We see strong market demand for our stability and texture solutions in Nutrition end markets, and we are extremely pleased with how our Health ingredients portfolio is performing in markets that exhibits solid underlying growth. In Minerals, both Alkali Chemicals and Lithium will deliver record annual volumes in 2014 as a result of our Operational Excellence programs. We see strong market demand in Lithium and favorable pricing trends in soda ash. We continue to expect segment revenues to increase in the mid- to high-single digits percentage and segment earnings to improve high-teens percent over 2013. I will now turn the call over to Paul to cover financial highlights.